The role of dihydrotestosterone in benign prostatic hyperplasiaCARSON, Culley III; RITTMASTER, Roger.Urology (Ridgewood, NJ). 2003, Vol 61, Num 4A, pp 2-7, issn 0090-4295, 6 p.Article

The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate CancerTINDALL, Donald J; RITTMASTER, Roger S.The Journal of urology. 2008, Vol 179, Num 4, pp 1235-1242, issn 0022-5347, 8 p.Article

Prostate-Specific Antigen Kinetics in Clinical Decision-Making During Active Surveillance for Early Prostate Cancer : A Review. CommentariesVAN DEN BERGH, Roderick C. N; ROEMELING, Stijn; ROOBOL, Monique J et al.European urology. 2008, Vol 54, Num 3, pp 505-516, issn 0302-2838, 12 p.Article

Effect of Dutasteride on Intraprostatic Androgen Levels in Men With Benign Prostatic Hyperplasia or Prostate CancerRITTMASTER, Roger; HAHN, Robert G; RAY, Paul et al.Urology (Ridgewood, NJ). 2008, Vol 72, Num 4, pp 808-812, issn 0090-4295, 5 p.Article

Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial. CommentaryCRAWFORD, E. David; ANDRIOLE, Gerald L; MARBERGER, Michael et al.Urology (Ridgewood, NJ). 2010, Vol 75, Num 3, pp 502-510, issn 0090-4295, 9 p.Article

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasiaMARBERGER, Michael; ROEHRBORN, Claus G; MARKS, Leonard S et al.The Journal of clinical endocrinology and metabolism. 2006, Vol 91, Num 4, pp 1323-1328, issn 0021-972X, 6 p.Article

PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial. CommentariesAUBIN, Sheila M. J; REID, Jennifer; VLAEMINCK-GUILLEM, Virginie et al.The Journal of urology. 2010, Vol 184, Num 5, pp 1947-1952, issn 0022-5347, 6 p.Article

Quantifying the impact of prostate volumes, number of biopsy cores and 5α-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modelingSERFLING, Robert; SHULMAN, Michael; THOMPSON, G. L et al.The Journal of urology. 2007, Vol 177, Num 6, pp 2352-2356, issn 0022-5347, 5 p.Article

Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trialANDRIOLE, Gerald; BOSTWICK, David; BRAWLEY, Otis et al.The Journal of urology. 2004, Vol 172, Num 4, pp 1314-1317, issn 0022-5347, 4 p., 1Article

Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasiaANDRIOLE, Gerald; BRUCHOVSKY, Nicholas; CHUNG, Leland W. K et al.The Journal of urology. 2004, Vol 172, Num 4, pp 1399-1403, issn 0022-5347, 5 p., 1Article

Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE StudyCURTIS NICKEL, J; ROEHRBORN, Claus; MONTORSI, Francesco et al.The Journal of urology. 2011, Vol 186, Num 4, pp 1313-1318, issn 0022-5347, 6 p., 1Article

Overexpression of 5α-ReductaseType I Increases Sensitivity of Prostate Cancer Cells to Low Concentrations of TestosteroneTHOMAS, Lynn N; DOUGLAS, Robert C; RITTMASTER, Roger S et al.The Prostate. 2009, Vol 69, Num 6, pp 595-602, issn 0270-4137, 8 p.Article

Pharmacological Approaches to Reducing the Risk of Prostate Cancer. CommentariesRITTMASTER, Roger S; FLESHNER, Neil E; THOMPSON, Ian M et al.European urology. 2009, Vol 55, Num 5, pp 1064-1074, issn 0302-2838, 11 p.Article

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trialFLESHNER, Neil E; LUCIA, M. Scott; EGERDIE, Blair et al.Lancet (British edition). 2012, Vol 379, Num 9821, pp 1103-1111, issn 0140-6736, 9 p.Article

The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms : Examination of Baseline Data from the REDUCE Trial. CommentaryNICKEL, J. Curtis; ROEHRBORN, Claus G; O'LEARY, Michael P et al.European urology. 2008, Vol 54, Num 6, pp 1379-1384, issn 0302-2838, 6 p.Article

Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) TrialROEHRBORN, Claus G; CURTIS NICKEL, J; ANDRIOLE, Gerald L et al.Urology (Ridgewood, NJ). 2011, Vol 78, Num 3, pp 641-646, issn 0090-4295, 6 p.Article

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)NICKEL, J. Curtis; GILLING, Peter; TAMMELA, Teuvo L et al.BJU international (Papier). 2011, Vol 108, Num 3, pp 388-394, issn 1464-4096, 7 p.Article

Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate CancerTHOMAS, Lynn N; DOUGLAS, Robert C; LAZIER, Catherine B et al.European urology. 2008, Vol 53, Num 2, pp 244-252, issn 0302-2838, 9 p.Article

The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss : Results of a randomized placebo-controlled study of dutasteride versus finasterideOLSEN, Elise A; HORDINSKY, Maria; WHITING, David et al.Journal of the American Academy of Dermatology. 2006, Vol 55, Num 6, pp 1014-1023, issn 0190-9622, 10 p.Article

Levels of 5α-Reductase Type 1 and Type 2 are Increased in Localized High Grade Compared to Low Grade Prostate CancerTHOMAS, Lynn N; DOUGLAS, Robert C; LAZIER, Catherine B et al.The Journal of urology. 2008, Vol 179, Num 1, pp 147-151, issn 0022-5347, 5 p.Article

The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE StudyANDRIOLE, Gerald L; BOSTWICK, David; FREEDLAND, Stephen J et al.The Journal of urology. 2011, Vol 185, Num 1, pp 126-131, issn 0022-5347, 6 p.Article

Genome-wide association study identifies a new locus JMJD1C at 10a21 that may influence serum androgen levels in menGUANGFU JIN; JIELIN SUN; RITTMASTER, Roger S et al.Human molecular genetics (Print). 2012, Vol 21, Num 23, pp 5222-5228, issn 0964-6906, 7 p.Article

Effect of Dutasteride on the Risk of Prostate CancerANDRIOLE, Gerald L; BOSTWICK, David G; SOMERVILLE, Matthew C et al.The New England journal of medicine. 2010, Vol 362, Num 13, pp 1192-1202, issn 0028-4793, 11 p.Article

Potential Impact of Adding Genetic Markers to Clinical Parameters in Predicting Prostate Biopsy Outcomes in Men Following an Initial Negative Biopsy: Findings from the REDUCE TrialKARIM KADER, A; JIELIN SUN; PLATEK, Greg T et al.European urology. 2012, Vol 62, Num 6, pp 953-961, issn 0302-2838, 9 p.Article